William Blair & Company
MACK

William Blair & Company’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

William Blair & Company’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-636
Closed -$56K – 2237
2014
Q4 		$56K Hold
636
– – ﹤0.01% 2045
2014
Q3 		$43K Buy
+636
New +$34K ﹤0.01% 2057

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

William Blair & Company's MACK Position: Q3 2017 in Review

William Blair & Company sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 7,506 shares — an estimated $73K sold.

William Blair & Company first reported a position in MACK in Q4 2013 and held it in 15 quarters. The position peaked at $4.47M in Q2 2015. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • William Blair & Company reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • William Blair & Company sold 7,506 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $73K.
  • William Blair & Company first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2013 and held it in 15 quarters.
  • William Blair & Company's Merrimack Pharmaceuticals, Inc. position peaked at $4.47M in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on William Blair & Company's 13F filing for Q3 2017, filed 13 Nov 2017.